Epidemiology versus genetics in Parkinson's disease: Progress in resolving an age-old debate

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Langston, J William ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CIGARETTE SMOKING; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; HUMAN; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL;

EID: 0031715849     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440707     Document Type: Conference Paper

References (54)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neeley, and Jones, 1817
2. Charcot J. Leçons sur les maladies du systeme nerveux. Paris: VA Delahaye, 1867
3. Friedman JH, Stern MB, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993:203-226
4. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's syndrome. Evidence for a single etiology related to subclinical infection about 1920. J Chron Dis 1963;16:961-973
5. Mjones H. Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol 1949;Suppl 54:1-195
6. Allen W. Inheritance of the shaking palsy. Arch Intern Med 1937;60:424-436
7. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980
8. Ward CD, Duvoisin RC, Ince SE, Nutt JG, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;335:815-824
9. Tanner CM, Marsden CD, Fahn S, eds. Movement disorders 3. Oxford: Butterworth Heinemann, 1994:124-146
10. Duvoisin RC. In: Stern MB, ed. Beyond the decade of the brain. Tunbridge Wells: Wells Medical, 1994:95-108
11. Golbe LI, Di Torio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;26:276-282
12. Golbe LI, Di Torio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-775
13. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-1199
14. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
15. Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the α-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998;50: 513-514
16. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13
17. Chan P, Jiang X, Forno LS, DiMonte DA, Tanner CM, Langston JW. Absence of mutation in the coding region of the alpha-synuclein gene in pathologically-proven Parkinson's disease. Neurology [in press]
18. Spellman GG. Report of familial cases of parkinsonism. Evidence of a dominant trait in a patient's family. JAMA 1962; 179:160-162
19. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism-dementia. Ann Neurol 1998;43:768-781
20. Farrer M, Wavrant-DeVrieze F, Crook R, et al. Low frequency of alpha-synuclein with familial Parkinson's disease. Ann Neurol 1998;43:394-397
21. Hrubec Z, Neel JV. Nance WE, eds. Twin research, part B: biology and epidemiology. New York: Alan R Liss, 1978:153-172
22. Tanner CM, Ottman R, Ellenberg JH, et al. Parkinson's disease (PD) concordance in elderly male monozygotic (MZ) and dizygotic (DZ) twins [abstract]. Neurology 1997;48:A333
23. Irwin I, Langston JW, Harvey AL, eds. Natural and synthetic neurotoxins. London: Academic Press, 1993:225-256
24. Heikkila RE, Youngster SK, Panek DU, Giovanni A, Sonsalla PK. Studies with the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogs. Toxicology 1988;49:493-501
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184
26. Koller WC, Lang AE. Age of onset of Parkinson's disease. Can J Neurol Sci 1987;14:179-180
27. Fall PA, Axelson O, Fredriksson M, et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996;49:637-641
28. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. BMJ 1986;292: 534-536
29. Carlsson A, Finch CE, Potter DE, Kenny AD, eds. Parkinson's disease-II: aging and neuroendocrine relations. New York: Plenum Press, 1978:1-13
30. Langston JW, Irwin I, Forno LS, et al. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. Florham Park, NJ; Macmillan Healthcare Information, 1987:59-74
31. Daly AK, Leathart JBS, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a hase substitution. Hum Genet 1995;95:337-341
32. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G. Gene-environment interaction in Parkinson's disease - the case of CYP2D6 gene polymorphisms. Adv Neurol 1996;69:61-72
33. Agundez JAG, Jimeniz-Jimeniz FJ, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298
34. Ray-Chaudhuri K, Smith C, Gough AC, et al. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1995;58:109
35. Gasser T, Muller-Myhsok B, Supala A, et al. The CYP2D6B allele is not over represented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520
36. Diederich N, Hilger C, Goetz CG, et al. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465
37. McCann SJ, Pond SM, James DG, LeCouteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 1997;153:50-53
38. Chan P, Tanner CM, Langston JW. Genetically determined differences in xenobiotic metabolism as a risk factor in Parkinson's disease [abstract]. Fund Appl Toxicol 1996;30(Suppl):89
39. Mannervik B, Danielson UH. Glutathione transferase: structure and catalytic activity. CRC Crit Rev Biochem 1988;23:283-337
40. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neuroepidemiology 1996;14:317-335
41. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46: 1275-1284
42. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-103
43. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci 1991;18:279-286
44. Corsini GU, Pintus S, Chiueh CC, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 1985;119:127-128
45. Irwin I, Di Monte DA, Thiruchelvam M, et al. Diethyldithiocarbamate (DDC): a promoter of dopaminergic toxicity [abstract]. Fund Appl Toxicol 1996;30(Suppl):263
46. Tanner CM, Kurland LT. In: Stern MB, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993:279-294
47. Garruto RM, Younghars R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology 1985;35:193-198
48. Zhang Z, Anderson DW, Lavine L, Mantel N. Patterns of acquiring parkinsonism-dementia complex on Guam: 1944 through 1985. Arch Neurol 1990;47:1019-1024
49. Garruto RM, Gajdusek DC, Chen KM. Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann Neurol 1980;8:612-619
50. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051
51. Sullivan JP, Tipton KF. Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B. Neurochem Res 1992;17:791-796
52. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245: 519-522
53. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
54. Duvoisin RC. In: Fahn S, Marsden CD, eds. Movement disorders. London: Butterworths Scientific, 1982:8-24